Subscribe to RSS
DOI: 10.1055/s-0032-1318345
Synthesis of N-Cbz-Substituted β3-Amino Ketones Utilizing 4-Substituted 1,3-Oxazinan-6-ones
Publication History
Received: 07 February 2013
Accepted after revision: 12 February 2013
Publication Date:
14 March 2013 (online)
Abstract
Stereoselective synthesis of N-Cbz-substituted β-amino ketones exploiting the versatile 1,3-oxazin-6-one scaffold is reported. The 4-substituted 1,3-oxazinan-6-ones were enolized and acylated diastereoselectively by addition of various acyl halides. Acidic decarboxylation was then employed to smoothly transform the 5-acylated products to chiral β-amino ketones. This methodology further highlights the utility of the 1,3-oxazinan-6-one as a scaffold to access valuable synthons that are used in the peptidomimetic field.
#
β-Amino ketones are important synthetic precursors for many syntheses[1] [2] and also have demonstrated biological activity.[ 3 ] There are numerous methods to gain access to β-amino ketones, such as Michael addition of an amine surrogate to an α,β-unsaturated ketone,[ 4 ] via a Mannich reaction,[2] [5] or by reduction of α,β-unsaturated ketones.[ 6 ] However, many of these methods are limited in their use and a large proportion do not produce chiral β-amino ketones. To overcome the shortcomings of previous syntheses, a stereoselective synthesis of β-amino ketones was devised, starting from 1,3-oxazinan-6-ones.
1,3-Oxazinan-6-ones have previously been utilized to produce a variety of different β-amino acid derivatives.[7] [8] [9] [10] The versatility of the 1,3-oxazinan-6-one scaffold has been shown to produce N-methyl β3-amino acids, 2-hydroxy,[ 9 ] 2-alkyl,[ 9 ] and 2,2-dialkyl β3-amino acids,[ 7 ] and recently β2,3-cyclic amino acids[ 10 ] (Scheme [1]). Ring opening of the 1,3-oxazinan-6-one has also been shown to produce a variety of carboxylic acids, esters, and amides.[7] [8] [9] [10] Herein the versatility of the 1,3-oxazinan-6-one is further exploited to produce chiral substituted β3-amino ketones.
It was proposed to produce the N-protected β3-amino ketones in two steps from the 1,3-oxazinan-6-one. Firstly, the 1,3-oxazinan-6-one would be enolized and then acylated by addition of an acyl halide. The 5-acylated oxazinanone would then be subjected to an acid-mediated ring opening followed by an in situ decarboxylation to produce the N-protected β-amino ketone (Scheme [2]).


The starting 1,3-oxazinan-6-ones 1–4 were easily prepared in three steps from the parent N-protected α-amino acids via the Arndt–Eistert homologation to produce the corresponding β-amino acids. The β-amino acids were then cyclized using a previously described method[7] [8] [9] [10] to afford the N-protected 4-substituted 1,3-oxazinan-6-ones 1–4.
The 5-position of the 1,3-oxazinan-6-one was then acylated using enolate chemistry.[ 11 ] Enolization of the 1,3-oxazinan-6-ones 1–4 was performed using LiHMDS as the base at –78 °C. The acyl halide was then added at –78 °C. The reaction was maintained at –78 °C for three hours before warming to –50 °C and quenching with an ammonium chloride solution (Table [1]).[ 11 ] A combination of the 4-substituted 1,3-oxazinan-6-ones 1–4 and various acyl halides were subjected to these conditions, and the results are shown in Table [1]. Moderate to good yields were obtained across a range of different substrates, however, the pivaloyl chloride used in entries 3, 6, and 9 consistently gave the lowest yields (30%, 43%, and 28%, respectively). Although the stereoselectivity of the 5-acylation reaction is not of relevance, because the stereocenter is removed in the next transformation to give the β-amino ketone, in all cases the trans isomer was produced with high diastereoselectivity (>95% dr, Table [1]). The trans selectivity was determined using coupling constants observed in the 1H NMR spectra. The trans selectivity has also been observed with both 5-alkylations and 5-hydroxylations of numerous 4-substituted 1,3-oxazinan-6-ones.[7] [9] [10]


a Reaction conditions: (a) 1. LiHMDS, THF, –78 °C, 40 min; 2. R2COCl, –78 °C to –50 °C, 3 h; 3. NH4Cl; (b) 2 M HCl, THF, 50 °C, 4–6 h.
The 5-acylated 1,3-oxazinan-6-ones 5–14 were then transformed into the β-amino ketones under mild acidic conditions (Table [1]).[ 12 ] The 5-acylated 1,3-oxazinan-6-ones 5–14 were dissolved in a mixture of THF and 2 M HCl, and the mixture was heated at 50 °C for 4–6 h. Under the acidic conditions the 1,3-oxazinan-6-one ring opens to produce the corresponding carboxylic acid. In situ decarboxylation of the β-keto carboxylic acid and hydrolysis of the iminium species then occurs to produce the β-amino ketone (Scheme [3]). The substituted β3-amino ketones 15–24 were all prepared in high yields (Table [1]).[12] [13]


In an extension of this work, it was proposed that an N-methyl β-amino ketone could also be produced using acidic conditions. It has been established that reductive cleavage of the 1,3-oxazinan-6-one ring employing BF3·OEt2 or TFA and triethylsilane produces N-methyl β-amino acids.[7] [8] [9] [10] It was proposed to use the same acidic reductive cleavage conditions to transform the 5-acylated 1,3-oxazinan-6-one 5 into the N-methyl β-amino ketone 25 (Scheme [4]). However, when this reaction was attempted the desired N-methyl β-amino ketone 25 was not obtained. The only product observed was the Cbz derivative of a secondary amine 27. This was formed via an iminium species 26 which is intercepted by a hydride anion from triethylsilane. Possible uses of this unexpected reaction are now being investigated.


To further elaborate the methodology demonstrated here to produce β-amino ketones, a 5-methylated 1,3-oxazinan-6-one 28 would be 5-acylated and then subsequently subjected to acidic conditions to produce a disubstituted β2,3-amino ketone. The previously synthesized 5-methyl 1,3-oxazinan-6-one 28 was produced using enolate chemistry and quenching with methyl triflate using established conditions.[7] [9] [10] The 5-methyl 1,3-oxazinan-6-one 28 was then enolized and 5-acylated using benzoyl chloride to afford 29 in moderate yield (40%). The 5,5-disubstituted 1,3-oxazinan-6-one 29 was then subjected to acidic conditions to produce the β-amino ketone as a mixture of diastereoisomers 30 and 31 in a good yield (82%, Scheme [5]). Although the stereochemistry was not the focus of this transformation, because the stereocenter is epimerized under the decarboxylation conditions, a sample of the trans isomer was obtained during purification. This transformation further demonstrates the capacity of this methodology to produce highly functionalized substituted β2,3-amino ketones.


In summary, the synthesis of chiral substituted β3-amino ketones 15–24 has been described starting from 4-substituted 1,3-oxazinan-6-ones 1–4. The 1,3-oxazinan-6-ones 1–4 were acylated using enolate chemistry to afford the 5-acylated 1,3-oxazinan-6-ones 5–14 in moderate to high yields. The 5-acylated products 5–14 were then smoothly transformed into the corresponding β-amino ketones 15–24, under acidic conditions. This methodology was further expanded to demonstrate that a disubstituted β2,3-amino ketone (30 and 31) could also be produced starting from the 5-methyl 4-substituted 1,3-oxazinan-6-one 28. The methodology described again highlights the versatility of the 1,3-oxazinan-6-one as a useful scaffold to access a diverse assortment of β-amino acids and β-amino ketones for use in the peptidomimetic field.
#
Acknowledgment
We thank La Trobe University for the provision of a postgraduate scholarship awarded to N.H.N. and the NHMRC (App. 1010326) for funding B.E.S.
Supporting Information
- for this article is available online at http://www.thieme-connect.com.accesdistant.sorbonne-universite.fr/ejournals/toc/synlett.
- Supporting Information
-
References and Notes
- 1a Barluenga J, Olano B, Fustero S. J. Org. Chem. 1985; 50: 4052
- 1b Bosch J, Rubiralta M, Domingo A, Sistaré J. J. Heterocycl. Chem. 1981; 18: 47
- 1c Brough P, Pécaut J, Rassat A, Rey P. Chem. Eur. J. 2006; 12: 5134
- 1d Fisyuk AS, Poendaev NV. Chem. Heterocycl. Compd. 2003; 39: 895
- 1e Fisyuk AS, Ryzhova EA, Unkovskii BV. Chem. Heterocycl. Compd. 2001; 37: 597
- 1f Hansen CP, Jensen AA, Balle T, Bitsch-Jensen K, Hassan MM, Liljefors T, Fralund B. Bioorg. Med. Chem. Lett. 2009; 19: 87
- 1g Holzgrabe U. Arch. Pharm. (Weinheim) 1988; 321: 767
- 1h Keck GE, Truong AP. Org. Lett. 2002; 4: 3131
- 1i King FD. Tetrahedron Lett. 1983; 24: 3281
- 1j Lanter JC, Chen H, Zhang X, Sui Z. Org. Lett. 2005; 7: 5905
- 1k Richards JJ, Ballard TE, Huigens RW, Melander C. ChemBioChem 2008; 9: 1267
- 1l Son P.-N, Lai JT. J. Org. Chem. 1981; 46: 323
- 1m Winter A, Risch N. Synthesis 2003; 2667
- 1n Yagi T, Aoyama T, Shioiri T. Synlett 1997; 1063
- 2 Webster SP, Binnie M, McConnell KM. M, Sooy K, Ward P, Greaney MF, Vinter A, Pallin TD, Dyke HJ, Gill MI. A, Warner I, Seckl JR, Walker BR. Bioorg. Med. Chem. Lett. 2010; 20: 3265
- 3a Du Y, Li Q, Xiong B, Hui X, Wang X, Feng Y, Meng T, Hu D, Zhang D, Wang M, Shen J. Bioorg. Med. Chem. 2010; 18: 4255
- 3b Makarova N, Boreko E, Moiseev I, Pavlova N, Zemtsova M, Nikolaeva S, Vladyko G. Pharm. Chem. J. 2001; 35: 480
- 3c Schönenberger H, Bastug T, Bindl L, Adelheid A, Adam D, Petter A, Zwez W. Pharm. Acta Helv. 1969; 44: 691
- 4a Davies SG, McCarthy TD. Synlett 1995; 7: 700
- 4b Davis FA, Yang B. Org. Lett. 2003; 5: 5011
- 4c Gomtsyan A. Org. Lett. 1999; 2: 11
- 4d Wabnitz TC, Spencer JB. Tetrahedron Lett. 2002; 43: 3891
- 5a Cardova A, Notz W, Zhong G, Betancort JM, Barbas CF. III. J. Am. Chem. Soc. 2002; 124: 1842
- 5b Das B, Reddy KR, Ramu R, Thirupathi P, Ravikanth B. Synlett 2006; 1756
- 5c Das B, Srilatha M, Veeranjaneyulu B, Rama RaoB. Synthesis 2010; 803
- 5d Davis FA, Yang B, Deng J, Zhang J. ARKIVOC 2006; (viii): 120
- 5e Eftekhari-Sis B, Abdollahifar A, Hashemi MM, Zirak M. Eur. J. Org. Chem. 2006; 5152
- 5f Hartman AE, Brophy CL, Cupp JA, Hodge DK, Peelen TJ. J. Org. Chem. 2009; 74: 3952
- 5g Jia X.-D, Wang X.-E, Yang C.-X, Huo C.-D, Wang W.-J, Ren Y, Wang X.-C. Org. Lett. 2010; 12: 732
- 5h Josephsohn NS, Snapper ML, Hoveyda AH. J. Am. Chem. Soc. 2004; 126: 3734
- 5i List B. J. Am. Chem. Soc. 2000; 122: 9336
- 5j List B, Pojarliev P, Biller WT, Martin HJ. J. Am. Chem. Soc. 2002; 124: 827
- 5k Lou S, Dai P, Schaus SE. J. Org. Chem. 2007; 72: 9998
- 5l Lou S, Taoka BM, Ting A, Schaus SE. J. Am. Chem. Soc. 2005; 127: 11256
- 5m Mei H, Xiong Y, Han J, Pan Y. Org. Biomol.Chem. 2010; 9: 1402
- 5n Notz W, Sakthivel K, Bui T, Zhong G, Barbas CF. III. Tetrahedron Lett. 2001; 42: 199
- 5o Ollevier T, Nadeau E. J. Org. Chem. 2004; 69: 9292
- 5p Ranu BC, Samanta S, Guchhait SK. Tetrahedron 2002; 58: 983
- 5q Schunk S, Enders D. Org. Lett. 2001; 3: 3177
- 5r Sieber JD, Morken JP. J. Am. Chem. Soc. 2005; 128: 74
- 5s Syu S.-e, Lee Y.-T, Jang Y.-J, Lin W. J. Org. Chem. 2011; 76: 2888
- 5t Terada M, Machioka K, Sorimachi K. Angew. Chem. Int. Ed. 2006; 45: 2254
- 5u Yang JW, Chandler C, Stadler M, Kampen D, List B. Nature (London) 2008; 452: 453
- 5v Yang J.-W, Stadler M, List B. Angew. Chem. Int. Ed. 2007; 46: 609
- 6 Geng H, Huang K, Sun T, Li W, Zhang X, Zhou L, Wu W, Zhang X. J. Org. Chem. 2011; 76: 332
- 7 Nguyen NH, Sleebs BE, Hughes AB. Tetrahedron 2012; 68: 4745
- 8a Sleebs BE, Hughes AB. Helv. Chim. Acta 2006; 89: 2611
- 8b Sleebs BE, Hughes AB. Aust. J. Chem. 2006; 58: 778
- 9 Sleebs BE, Hughes AB. J. Org. Chem. 2007; 72: 3340
- 10 Sleebs BE, Nguyen NH, Hughes AB. Tetrahedron 2013; 69: in press
- 11 General Procedure 1 5-Acylation of 1,3-Oxazinan-6-ones A solution of the 1,3-oxazinan-6-one 1–4 (0.1 M in dry freshly distilled THF) was cooled to –78 °C under an argon atmosphere. Then LiHMDS (1.1 equiv of a 1.0 M solution in THF) was added dropwise, and the solution was left to stir at –78 °C for 40 min. The acylating agent (3.0 equiv) was then added dropwise and stirring was continued for 3 h at –78 °C. The solution was then allowed to warm to –50 °C, and the reaction was then quenched with sat. NH4Cl solution (5 mL). The solution was diluted with EtOAc (20 mL) and washed with H2O (20 mL). The organic layer was dried (MgSO4) and concentrated in vacuo to give an oil. The oil was subjected to flash column chromatography, eluting with 5–30% EtOAc–hexane. Data for (4S,5R)-N-Benzyloxycarbonyl-4-isopropyl-5-propionyl-1,3-oxazinan-6-one (5) General Procedure 1 was followed for the acylation of oxazinanone 1 (63 mg, 0.23 mmol) with propionyl chloride (59.8 μL, 0.68 mmol), to afford the desired 5-substituted 1,3-oxazinan-6-one 5 as a clear oil (crystallized on standing; 60 mg, 80% yield); mp 82–84 °C; Rf = 0.23 (20% EtOAc–hexane); [α]D 25 +116 (c 2.17, MeOH). 1H NMR (300 MHz, CDCl3): δ = 7.33 (s, 5 H), 5.93 (d, 1 H, J = 9.9 Hz), 5.17 (s, 2 H), 4.93 (d, 1 H, J = 9.9 Hz), 4.59 (t, 1 H, J = 7.2 Hz), 3.73 (d, 1 H, J = 7.2 Hz), 2.84–2.73 (m, 1 H), 2.58–2.47 (m, 1 H), 1.88–1.77 (m, 1 H), 1.09 (t, 3 H, J = 7.2 Hz), 0.89 (d, 3 H, J = 7.2 Hz), 0.85 (d, 3 H, J = 7.2 Hz). 13C NMR (75 MHz, CDCl3): δ = 202.7 167.3, 154.5, 134.9, 128.3, 128.1, 127.8, 72.9, 68.2, 55.9, 55.1, 36.5, 31.0, 18.3, 18.1, 7.2. IR (film): νmax = 2967, 2940, 1748, 1717, 1458, 1412, 1258, 1123, 979 cm–1. HRMS (ESI–): m/z calcd for C18H23NO5 [M – H]–: 332.1503; found: 332.1496.
- 12
General Procedure 2
Formation of the β3-Amino Ketones The oxazinanone 15–24 was dissolved in a mixture of THF–2 M HCl (1:1, 0.013 M solution), and the reaction mixture was gently heated to 50 °C for 4–6 h. The THF was then removed under reduced pressure. The aqueous solution was taken up EtOAc and washed with H2O (3 × 10 mL) followed by brine (1 × 10 mL). The organic layer was dried (MgSO4) and evaporated in vacuo to give an oil. The oil was subjected to flash column chromatography, eluting with 5–20% EtOAc–hexane. - 13 Data for (5R)-(N-Benzyloxylcarbonyl-5-amino)-6-methyl-heptan-2-one (15) General Procedure 2 was followed for the hydrolysis of the 1,3-oxazinan-6-one 5 (31 mg, 0.09 mmol), and afforded the β-amino ketone 15 as a white solid (24 mg, 92% yield); mp 75–77 °C; Rf = 0.50 (30% EtOAc–hexane); [α]D 25 –3.6 (c 1.09, MeOH). 1H NMR (300 MHz, CDCl3): δ = 7.32–7.27 (m, 5 H), 5.14 (d, 1 H, J = 8.9 Hz), 5.06 (s, 2 H), 3.83–3.76 (m, 1 H), 2.61 (br d, 2 H, J = 5.7 Hz), 2.47–2.33 (m, 2 H), 1.89–1.80 (m, 1 H), 1.00 (t, 3 H, J = 7.2 Hz), 0.89 (d, 3 H, J = 4.2 Hz), 0.87 (d, 3 H, J = 4.5 Hz). 13C NMR (75 MHz, CDCl3): δ = 210.0, 155.7, 136.3, 128.1, 127.6, 127.5, 66.2, 53.2, 43.9, 35.8, 31.2, 19.1, 18.2, 7.3. IR (film): νmax = 3325, 2940, 2878, 1709, 1682, 2539, 1454, 1416, 1308. HRMS (ESI+): m/z calcd for C16H23NO3 [M + H]+: 278.1751; found: 278.1756. HPLC [Chiralpak AD-H, PE–2-PrOH (90:10), 25 °C, 254 nm]: t R (major) = 7.1 min; t R (minor) = 6.1 min, 97% ee.
-
References and Notes
- 1a Barluenga J, Olano B, Fustero S. J. Org. Chem. 1985; 50: 4052
- 1b Bosch J, Rubiralta M, Domingo A, Sistaré J. J. Heterocycl. Chem. 1981; 18: 47
- 1c Brough P, Pécaut J, Rassat A, Rey P. Chem. Eur. J. 2006; 12: 5134
- 1d Fisyuk AS, Poendaev NV. Chem. Heterocycl. Compd. 2003; 39: 895
- 1e Fisyuk AS, Ryzhova EA, Unkovskii BV. Chem. Heterocycl. Compd. 2001; 37: 597
- 1f Hansen CP, Jensen AA, Balle T, Bitsch-Jensen K, Hassan MM, Liljefors T, Fralund B. Bioorg. Med. Chem. Lett. 2009; 19: 87
- 1g Holzgrabe U. Arch. Pharm. (Weinheim) 1988; 321: 767
- 1h Keck GE, Truong AP. Org. Lett. 2002; 4: 3131
- 1i King FD. Tetrahedron Lett. 1983; 24: 3281
- 1j Lanter JC, Chen H, Zhang X, Sui Z. Org. Lett. 2005; 7: 5905
- 1k Richards JJ, Ballard TE, Huigens RW, Melander C. ChemBioChem 2008; 9: 1267
- 1l Son P.-N, Lai JT. J. Org. Chem. 1981; 46: 323
- 1m Winter A, Risch N. Synthesis 2003; 2667
- 1n Yagi T, Aoyama T, Shioiri T. Synlett 1997; 1063
- 2 Webster SP, Binnie M, McConnell KM. M, Sooy K, Ward P, Greaney MF, Vinter A, Pallin TD, Dyke HJ, Gill MI. A, Warner I, Seckl JR, Walker BR. Bioorg. Med. Chem. Lett. 2010; 20: 3265
- 3a Du Y, Li Q, Xiong B, Hui X, Wang X, Feng Y, Meng T, Hu D, Zhang D, Wang M, Shen J. Bioorg. Med. Chem. 2010; 18: 4255
- 3b Makarova N, Boreko E, Moiseev I, Pavlova N, Zemtsova M, Nikolaeva S, Vladyko G. Pharm. Chem. J. 2001; 35: 480
- 3c Schönenberger H, Bastug T, Bindl L, Adelheid A, Adam D, Petter A, Zwez W. Pharm. Acta Helv. 1969; 44: 691
- 4a Davies SG, McCarthy TD. Synlett 1995; 7: 700
- 4b Davis FA, Yang B. Org. Lett. 2003; 5: 5011
- 4c Gomtsyan A. Org. Lett. 1999; 2: 11
- 4d Wabnitz TC, Spencer JB. Tetrahedron Lett. 2002; 43: 3891
- 5a Cardova A, Notz W, Zhong G, Betancort JM, Barbas CF. III. J. Am. Chem. Soc. 2002; 124: 1842
- 5b Das B, Reddy KR, Ramu R, Thirupathi P, Ravikanth B. Synlett 2006; 1756
- 5c Das B, Srilatha M, Veeranjaneyulu B, Rama RaoB. Synthesis 2010; 803
- 5d Davis FA, Yang B, Deng J, Zhang J. ARKIVOC 2006; (viii): 120
- 5e Eftekhari-Sis B, Abdollahifar A, Hashemi MM, Zirak M. Eur. J. Org. Chem. 2006; 5152
- 5f Hartman AE, Brophy CL, Cupp JA, Hodge DK, Peelen TJ. J. Org. Chem. 2009; 74: 3952
- 5g Jia X.-D, Wang X.-E, Yang C.-X, Huo C.-D, Wang W.-J, Ren Y, Wang X.-C. Org. Lett. 2010; 12: 732
- 5h Josephsohn NS, Snapper ML, Hoveyda AH. J. Am. Chem. Soc. 2004; 126: 3734
- 5i List B. J. Am. Chem. Soc. 2000; 122: 9336
- 5j List B, Pojarliev P, Biller WT, Martin HJ. J. Am. Chem. Soc. 2002; 124: 827
- 5k Lou S, Dai P, Schaus SE. J. Org. Chem. 2007; 72: 9998
- 5l Lou S, Taoka BM, Ting A, Schaus SE. J. Am. Chem. Soc. 2005; 127: 11256
- 5m Mei H, Xiong Y, Han J, Pan Y. Org. Biomol.Chem. 2010; 9: 1402
- 5n Notz W, Sakthivel K, Bui T, Zhong G, Barbas CF. III. Tetrahedron Lett. 2001; 42: 199
- 5o Ollevier T, Nadeau E. J. Org. Chem. 2004; 69: 9292
- 5p Ranu BC, Samanta S, Guchhait SK. Tetrahedron 2002; 58: 983
- 5q Schunk S, Enders D. Org. Lett. 2001; 3: 3177
- 5r Sieber JD, Morken JP. J. Am. Chem. Soc. 2005; 128: 74
- 5s Syu S.-e, Lee Y.-T, Jang Y.-J, Lin W. J. Org. Chem. 2011; 76: 2888
- 5t Terada M, Machioka K, Sorimachi K. Angew. Chem. Int. Ed. 2006; 45: 2254
- 5u Yang JW, Chandler C, Stadler M, Kampen D, List B. Nature (London) 2008; 452: 453
- 5v Yang J.-W, Stadler M, List B. Angew. Chem. Int. Ed. 2007; 46: 609
- 6 Geng H, Huang K, Sun T, Li W, Zhang X, Zhou L, Wu W, Zhang X. J. Org. Chem. 2011; 76: 332
- 7 Nguyen NH, Sleebs BE, Hughes AB. Tetrahedron 2012; 68: 4745
- 8a Sleebs BE, Hughes AB. Helv. Chim. Acta 2006; 89: 2611
- 8b Sleebs BE, Hughes AB. Aust. J. Chem. 2006; 58: 778
- 9 Sleebs BE, Hughes AB. J. Org. Chem. 2007; 72: 3340
- 10 Sleebs BE, Nguyen NH, Hughes AB. Tetrahedron 2013; 69: in press
- 11 General Procedure 1 5-Acylation of 1,3-Oxazinan-6-ones A solution of the 1,3-oxazinan-6-one 1–4 (0.1 M in dry freshly distilled THF) was cooled to –78 °C under an argon atmosphere. Then LiHMDS (1.1 equiv of a 1.0 M solution in THF) was added dropwise, and the solution was left to stir at –78 °C for 40 min. The acylating agent (3.0 equiv) was then added dropwise and stirring was continued for 3 h at –78 °C. The solution was then allowed to warm to –50 °C, and the reaction was then quenched with sat. NH4Cl solution (5 mL). The solution was diluted with EtOAc (20 mL) and washed with H2O (20 mL). The organic layer was dried (MgSO4) and concentrated in vacuo to give an oil. The oil was subjected to flash column chromatography, eluting with 5–30% EtOAc–hexane. Data for (4S,5R)-N-Benzyloxycarbonyl-4-isopropyl-5-propionyl-1,3-oxazinan-6-one (5) General Procedure 1 was followed for the acylation of oxazinanone 1 (63 mg, 0.23 mmol) with propionyl chloride (59.8 μL, 0.68 mmol), to afford the desired 5-substituted 1,3-oxazinan-6-one 5 as a clear oil (crystallized on standing; 60 mg, 80% yield); mp 82–84 °C; Rf = 0.23 (20% EtOAc–hexane); [α]D 25 +116 (c 2.17, MeOH). 1H NMR (300 MHz, CDCl3): δ = 7.33 (s, 5 H), 5.93 (d, 1 H, J = 9.9 Hz), 5.17 (s, 2 H), 4.93 (d, 1 H, J = 9.9 Hz), 4.59 (t, 1 H, J = 7.2 Hz), 3.73 (d, 1 H, J = 7.2 Hz), 2.84–2.73 (m, 1 H), 2.58–2.47 (m, 1 H), 1.88–1.77 (m, 1 H), 1.09 (t, 3 H, J = 7.2 Hz), 0.89 (d, 3 H, J = 7.2 Hz), 0.85 (d, 3 H, J = 7.2 Hz). 13C NMR (75 MHz, CDCl3): δ = 202.7 167.3, 154.5, 134.9, 128.3, 128.1, 127.8, 72.9, 68.2, 55.9, 55.1, 36.5, 31.0, 18.3, 18.1, 7.2. IR (film): νmax = 2967, 2940, 1748, 1717, 1458, 1412, 1258, 1123, 979 cm–1. HRMS (ESI–): m/z calcd for C18H23NO5 [M – H]–: 332.1503; found: 332.1496.
- 12
General Procedure 2
Formation of the β3-Amino Ketones The oxazinanone 15–24 was dissolved in a mixture of THF–2 M HCl (1:1, 0.013 M solution), and the reaction mixture was gently heated to 50 °C for 4–6 h. The THF was then removed under reduced pressure. The aqueous solution was taken up EtOAc and washed with H2O (3 × 10 mL) followed by brine (1 × 10 mL). The organic layer was dried (MgSO4) and evaporated in vacuo to give an oil. The oil was subjected to flash column chromatography, eluting with 5–20% EtOAc–hexane. - 13 Data for (5R)-(N-Benzyloxylcarbonyl-5-amino)-6-methyl-heptan-2-one (15) General Procedure 2 was followed for the hydrolysis of the 1,3-oxazinan-6-one 5 (31 mg, 0.09 mmol), and afforded the β-amino ketone 15 as a white solid (24 mg, 92% yield); mp 75–77 °C; Rf = 0.50 (30% EtOAc–hexane); [α]D 25 –3.6 (c 1.09, MeOH). 1H NMR (300 MHz, CDCl3): δ = 7.32–7.27 (m, 5 H), 5.14 (d, 1 H, J = 8.9 Hz), 5.06 (s, 2 H), 3.83–3.76 (m, 1 H), 2.61 (br d, 2 H, J = 5.7 Hz), 2.47–2.33 (m, 2 H), 1.89–1.80 (m, 1 H), 1.00 (t, 3 H, J = 7.2 Hz), 0.89 (d, 3 H, J = 4.2 Hz), 0.87 (d, 3 H, J = 4.5 Hz). 13C NMR (75 MHz, CDCl3): δ = 210.0, 155.7, 136.3, 128.1, 127.6, 127.5, 66.2, 53.2, 43.9, 35.8, 31.2, 19.1, 18.2, 7.3. IR (film): νmax = 3325, 2940, 2878, 1709, 1682, 2539, 1454, 1416, 1308. HRMS (ESI+): m/z calcd for C16H23NO3 [M + H]+: 278.1751; found: 278.1756. HPLC [Chiralpak AD-H, PE–2-PrOH (90:10), 25 °C, 254 nm]: t R (major) = 7.1 min; t R (minor) = 6.1 min, 97% ee.










